TransCode Therapeutics to Present Updated Phase 1a TTX-MC138 Data at ESMO Congress 2026

TransCode Therapeutics will present updated Phase 1a clinical data for its lead candidate TTX-MC138 at the ESMO Congress 2026, highlighting the potential of its miR-10b targeting approach for metastatic cancers.

Chicago Metrowire Staff
••Healthcare
TransCode Therapeutics to Present Updated Phase 1a TTX-MC138 Data at ESMO Congress 2026

TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, announced that a poster featuring its lead therapeutic candidate, TTX-MC138, will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on Oct. 23 in Madrid, Spain. The presentation will highlight the latest clinical update from the Phase 1a trial evaluating TTX-MC138 in patients with advanced solid tumors.

TTX-MC138 is an investigational therapeutic designed to target miR-10b, a microRNA associated with metastatic disease progression. The ESMO Congress is a significant platform for presenting oncology data, and the updated Phase 1a results could provide important insights into the safety and early efficacy of TTX-MC138. For TransCode Therapeutics, this presentation represents a key milestone in the clinical development of its lead candidate and may enhance the company's visibility among oncologists, researchers, and investors.

The Phase 1a trial is evaluating TTX-MC138 in patients with advanced solid tumors, a population with high unmet need. Metastatic disease remains a major challenge in oncology, and therapies that specifically target drivers of metastasis, such as miR-10b, are of considerable interest. TransCode's approach aims to address this by targeting a well-documented biomarker of metastasis. The updated data to be presented at ESMO could offer the first clinical evidence of TTX-MC138's activity in humans, which would be a critical step for the program.

TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. Its lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. The company's focus on RNA-based therapeutics aligns with growing interest in nucleic acid therapies for cancer.

The announcement comes as investors and industry observers closely monitor clinical progress in the RNA therapeutics space. Positive data could bolster confidence in TransCode's platform and potentially attract partnership or financing opportunities. The latest news and updates relating to RNAZ are available in the company's newsroom at https://nnw.fm/RNAZ.

NetworkNewsWire (NetworkNewsWire) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions.

Blockchain Registration

QR Code for Blockchain Registration